All In Biotech

Drug Trial Radar · NCT06592768

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

17

Actual

Start

Nov 26, 2024

Primary completion

Aug 11, 2025

Study completion Aug 11, 2025

Sponsor

Lead sponsor
Jasper Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model. A single dose proof of concept approach at a dose level shown to be biologically active should inform the impact of briquilimab on allergic asthma as compared to placebo while minimizing exposure to participants, in a new indication.

Conditions

  • Allergic Asthma

Interventions

  • BriquilimabDrug

    Subcutaneous Administration

  • Placebo ComparatorOther

    Subcutaneous Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participantsTime frame: From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 4.5 months)
  2. To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LARTime frame: 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
  3. To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LARTime frame: 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Calgary

    Calgary, Alberta, Canada

  • University of Alberta

    Edmonton, Alberta, Canada

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • McMaster University

    Hamilton, Ontario, Canada

  • University of Laval

    Québec, Quebec, Canada

  • University of Saskatchewan

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.